Daratumumab in light chain deposition disease: rapid and profound hematologic response preserves kidney function

類似資料

• Indicators of profound hematologic response in AL amyloidosis: complete response remains the goal of therapy
  著者:: Milani, Paolo, 等
  出版事項: (2020)
• Daratumumab in the Treatment of Light-Chain (AL) Amyloidosis
  著者:: Palladini, Giovanni, 等
  出版事項: (2021)
• Sequential response-driven bortezomib-based therapy followed by autologous stem cell transplant in AL amyloidosis
  著者:: Basset, Marco, 等
  出版事項: (2020)
• A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis
  著者:: Palladini, Giovanni, 等
  出版事項: (2013)
• Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach
  著者:: Palladini, Giovanni, 等
  出版事項: (2014)